Reaching the sea, the sun and the end - Day 7 C2K

Dust, stars and crocodiles – Days 5 & 6 C2K

The roads, the dust and the crash - days 3 & 4 C2K

Dodgy eyes, taipans and a COVID moment - days 1 & 2 C2K

Stroking my ageing ego: pre-ride training for the C2K

Fair dinkum or collywobbles? Life sciences and the Australia – UK free trade agreement

Opportunities for the Life Science Industry in Australia post-COVID

More risk for government this time around in agreement negotiation

It's just the vibe: soft skills in the art of government-business relations

Ethics own goal in opioid epidemic: the role of consultants

5 Trends for Life Science Companies to Watch in 2021

Submission to Australian House of Representatives inquiry into approval processes for new drugs

‘Roll with the punches and get to what’s real’: reflections on 2020

COVID-19 vaccination a 12-month success for science, governments and industry

A little less conversation, a little more action please: the global state of AMR

Non-communicable diseases and the global countdown to 2030

The next 20-year PBS agenda: government commitments to new medicines spending

PBS New Medicines Funding Guarantee: echoes of elections past ...

The new frontier: emerging regulatory issues in cell and gene therapies

This could get messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing